BRCA1
basal-like
expression
prognosis
promoter hypermethylation
triple-negative breast cancer
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
30 Mar 2020
30 Mar 2020
Historique:
received:
02
03
2020
revised:
25
03
2020
accepted:
26
03
2020
entrez:
3
4
2020
pubmed:
3
4
2020
medline:
3
4
2020
Statut:
epublish
Résumé
The aberrant hypermethylation of
Identifiants
pubmed: 32235500
pii: cancers12040828
doi: 10.3390/cancers12040828
pmc: PMC7225997
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : AstraZeneca
ID : NCR-18-14012
Organisme : Ligue Contre le Cancer
ID : Comités Aude et Hérault 2014
Déclaration de conflit d'intérêts
WJ: Research funding (Astra Zeneca), honoraria (Astra Zeneca, Pfizer), travel grants (Astra Zeneca, Pfizer). PJL: Grants (Agena Bioscience), honoraria (AstraZeneca, Bristol Meyer Squibb, Roche, Agena Bioscience). All other authors declare that they have no competing interests.
Références
Cell. 2003 Nov 26;115(5):523-35
pubmed: 14651845
Mol Clin Oncol. 2015 Nov;3(6):1353-1360
pubmed: 26807247
Breast Cancer Res. 2014 Sep 17;16(5):435
pubmed: 25228385
Nature. 2011 Jun 29;474(7353):609-15
pubmed: 21720365
J Natl Cancer Inst. 2011 Feb 16;103(4):334-46
pubmed: 21183737
Oncoimmunology. 2018 Sep 11;7(12):e1509820
pubmed: 30524905
Cancer Discov. 2012 Apr;2(4):366-375
pubmed: 22576213
Clin Cancer Res. 2008 Mar 1;14(5):1368-76
pubmed: 18316557
J Clin Pathol. 2001 Jun;54(6):476-80
pubmed: 11376024
J Clin Oncol. 2010 Oct 10;28(29):e563-4; author reply e565-6
pubmed: 20679605
J Natl Cancer Inst. 2000 Apr 5;92(7):564-9
pubmed: 10749912
N Engl J Med. 2019 Mar 7;380(10):987-988
pubmed: 30855757
Am J Clin Oncol. 2010 Dec;33(6):637-45
pubmed: 20023571
Histopathology. 2016 Apr;68(5):702-12
pubmed: 26259780
Ann Oncol. 2005 Oct;16(10):1569-83
pubmed: 16148022
BMC Cancer. 2013 Nov 05;13:523
pubmed: 24191908
Histopathology. 2010 Sep;57(3):363-70
pubmed: 20840667
Sci Rep. 2015 Dec 08;5:17869
pubmed: 26643130
Am J Hum Genet. 2018 Aug 2;103(2):213-220
pubmed: 30075112
Lancet. 2010 Jul 24;376(9737):235-44
pubmed: 20609467
Breast Cancer Res Treat. 2015 Apr;150(3):479-86
pubmed: 25783183
Clin Cancer Res. 2007 Apr 15;13(8):2329-34
pubmed: 17438091
EMBO Mol Med. 2011 May;3(5):279-90
pubmed: 21472990
J Histochem Cytochem. 2005 May;53(5):621-9
pubmed: 15872055
Virchows Arch. 2013 Mar;462(3):269-79
pubmed: 23354597
BMC Cancer. 2015 Oct 21;15:755
pubmed: 26490435
J Biol Chem. 1997 Aug 22;272(34):20994-7
pubmed: 9261099
Br J Cancer. 2018 Jul;119(1):76-79
pubmed: 29880907
Int J Biol Markers. 2006 Jan-Mar;21(1):20-9
pubmed: 16711510
Nature. 2000 Aug 17;406(6797):747-52
pubmed: 10963602
Nat Med. 2018 May;24(5):628-637
pubmed: 29713086
PLoS One. 2016 Apr 14;11(4):e0153113
pubmed: 27077368
Cancer Res. 2013 Apr 1;73(7):2025-30
pubmed: 23536562
Cancer Chemother Pharmacol. 2011 Sep;68(3):753-61
pubmed: 21170648
Lancet Oncol. 2011 Sep;12(9):852-61
pubmed: 21862407
Ann Oncol. 2014 Dec;25(12):2372-8
pubmed: 25281711
Int J Gynecol Cancer. 2018 Oct;28(8):1514-1519
pubmed: 30045136
PLoS One. 2014 Jan 27;9(1):e87039
pubmed: 24475217
Br J Cancer. 1997;76(9):1150-6
pubmed: 9365162
Cancer Immunol Res. 2014 Apr;2(4):361-70
pubmed: 24764583
Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4429-34
pubmed: 17671126
Am J Surg Pathol. 2013 Jan;37(1):138-46
pubmed: 23232854
JAMA. 2011 Oct 12;306(14):1557-65
pubmed: 21990299
Hum Pathol. 2008 Jun;39(6):857-65
pubmed: 18400253
Virchows Arch. 2012 Sep;461(3):305-12
pubmed: 22820987
Br J Cancer. 2013 May 28;108(10):2172-7
pubmed: 23558900
Clin Breast Cancer. 2015 Dec;15(6):498-504
pubmed: 26195437
Breast Cancer Res. 2012 Jul 20;14(4):R110
pubmed: 22817698
Cancer Biol Ther. 2006 May;5(5):505-10
pubmed: 16582598
Nat Rev Cancer. 2008 Mar;8(3):193-204
pubmed: 18256616
Epigenetics. 2012 Nov;7(11):1225-9
pubmed: 23069641
Breast Cancer Res. 2006;8(4):R38
pubmed: 16846527
Life Sci. 2007 Jul 4;81(4):280-7
pubmed: 17599361
Anal Biochem. 2008 Oct 15;381(2):240-7
pubmed: 18674509
Carcinogenesis. 2000 Feb;21(2):147-51
pubmed: 10657950
Carcinogenesis. 2000 Sep;21(9):1761-5
pubmed: 10964110
J Clin Oncol. 2002 May 1;20(9):2310-8
pubmed: 11981002
Cancer Res. 2005 Dec 1;65(23):10692-9
pubmed: 16322213
Nat Commun. 2018 Sep 28;9(1):3970
pubmed: 30266954
Crit Rev Oncol Hematol. 2012 Jun;82(3):361-9
pubmed: 22024387
Int J Gynecol Cancer. 2017 Oct;27(8):1658-1665
pubmed: 28691938
N Engl J Med. 2017 Dec 21;377(25):2500-2501
pubmed: 29262275
Ann Oncol. 2013 Jun;24(6):1498-505
pubmed: 23406733
Breast Cancer Res. 2011 Feb 02;13(1):R15
pubmed: 21288332
Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74
pubmed: 11553815
Oncotarget. 2016 May 10;7(19):27499-510
pubmed: 27027444
Ann Oncol. 2011 Apr;22(4):870-6
pubmed: 20937646
N Engl J Med. 2017 Aug 10;377(6):523-533
pubmed: 28578601
Nat Rev Cancer. 2004 Oct;4(10):814-9
pubmed: 15510162
Breast Cancer Res Treat. 2012 Aug;135(1):93-102
pubmed: 22538771
Breast Cancer Res Treat. 2013 Sep;141(2):205-12
pubmed: 24026861
Oncotarget. 2016 Apr 12;7(15):20068-79
pubmed: 26933805
N Engl J Med. 2018 Aug 23;379(8):753-763
pubmed: 30110579
Oncologist. 2013;18(2):123-33
pubmed: 23404817
Cancer. 2020 Jan 15;126(2):271-280
pubmed: 31581314
Endocr Relat Cancer. 2016 Sep;23(9):R381-92
pubmed: 27412917